OPRX OptimizeRx Corporation

OPTIMIZERx Corp. (OTCBB: OPRX) announced additional investment commitments of up to $10 million to further support the company's exciting growth opportunities relating to SampleMD's success in the market place.

Since its launch in 4Q 2010, SampleMD has become the exclusive technology within leading health systems, Electronic Health Records (EHRs) and ePrescribing systems to allow doctors to electronically add and distribute a savings eVoucher, co-pay coupon or other patient support right with the prescription.

Based on the company's planned integration of SampleMD's eCouponing technology within other EHRs and health systems, along with the escalating uptake of electronic prescribing adaption and incentives, the company seeks to distribute 100,000 eCoupon and savings vouchers monthly by 3Q 2012.

"With independent projections of over 2 billion electronic prescriptions annually by 2016 combined with SampleMD's unique technology to add an eCoupon to help patients actually fill them, this additional capital commitment allows us to fully exploit the huge market potential," stated David Harrell, Chairman of OPTIMZERx Corp.

Pharmaceutical manufacturers have also recognized these technology trends along with SampleMD's unique capabilities to promote their products and patient support right at point of prescription. To date, the company has contractually secured over 60 brand patient savings offers from leading manufacturers like Merck, Novartis, Bayer, Abbott and Lilly. The pipeline continues to grow as more products and blockbusters like Pradaxa are being added.

About OPTIMIZERx Corp.

OPTIMIZERx Corp. provides unique consumer and physician platforms to help patients better afford and comply with their medicines and healthcare products, while offering pharmaceutical and healthcare companies effective ways to expand patient awareness, access and adherence to their brands. For more information, please go to www.optimizerxcorp.com.

'SAFE HARBOR'

This press release contains forward-looking statements within the definition of Section 27A of the Securities Act of 1933, as amended and such section 21E of the Securities Act of 1934, amended. These forward-looking statements should not be used to make an investment decision. The words 'estimate,' 'possible' and 'seeking' and similar expressions identify forward-looking statements, which speak only as to the date the statement was made. The company undertakes no obligation to publicly update or revise any forward-looking statements, whether because of new information, future events, or otherwise. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted, or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward-looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks.

Contact: David Lester Email Contact 248.651.6568